This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Bank of America Securities Sticks to Their Sell Rating for CureVac (CVAC)

Tipranks - Tipranks - Thu May 22, 2025

Bank of America Securities analyst Alec Stranahan reiterated a Sell rating on CureVac (CVAC – Research Report) yesterday and set a price target of $2.50. The company’s shares closed yesterday at $4.28.

Confident Investing Starts Here:

Stranahan covers the Healthcare sector, focusing on stocks such as Novavax, Beam Therapeutics, and Candel Therapeutics. According to TipRanks, Stranahan has an average return of -12.1% and a 34.60% success rate on recommended stocks.

The word on The Street in general, suggests a Hold analyst consensus rating for CureVac with a $8.17 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.28 and a one-year low of $2.37. Currently, CureVac has an average volume of 627K.

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVAC in relation to earlier this year.

Read More on CVAC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).